Complex systems, evolution, and animal models

Studies in History and Philosophy of Science Part C :Studies in History and Philosophy of Biological and Biomedical Sciences

Volumn 42, Issue 4, 2011, Pages 542-544

  Greek, Ray ^a   Shanks, Niall ^b  

^a Americans For Medical Advancement   (United States)

^b WICHITA STATE UNIVERSITY   (United States)

Author keywords

Animal models; Complex systems; Evolution; Medicine; Prediction

Indexed keywords

ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; EVOLUTION; HUMAN; NOTE; STATISTICS; SYSTEMS BIOLOGY;

ANIMALS; BIOLOGICAL EVOLUTION; HUMANS; MODELS, ANIMAL; MODELS, BIOLOGICAL; STATISTICS AS TOPIC; SYSTEMS BIOLOGY;

EID: 82555172451     PISSN: 13698486     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.shpsc.2011.07.001     Document Type: Note

References (42)

1. Agarwal S., Moorchung N. Modifier genes and oligogenic disease. Journal of Nippon Medical School 2005, 72:326-334.
2. Boone C., Bussey H., Andrews B.J. Exploring genetic interactions and networks with yeast. Nature Reviews Genetics 2007, 8:437-449.
3. Bruder C.E., Piotrowski A., Gijsbers A.A., Andersson R., Erickson S., de Stahl T.D., et al. Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. American Journal of Human Genetics 2008, 82:763-771.
4. Cheung D.S., Warman M.L., Mulliken J.B. Hemangioma in twins. Annals of Plastic Surgery 1997, 38:269-274.
5. Dixit R., Boelsterli U. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discovery Today 2007, 12:336-342.
6. Dowell R.D., Ryan O., Jansen A., Cheung D., Agarwala S., Danford T., et al. Genotype to phenotype: A complex problem. Science 2010, 328:469.
7. Editorial End of the interlude?. Nature Biotechnology 2004, 22:1191.
8. Ennever F.K., Noonan T.J., Rosenkranz H.S. The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans. Mutagenesis 1987, 2:73-78.
9. Fletcher A.P. Drug safety tests and subsequent clinical experience. Journal of the Royal Society of Medicine 1978, 71:693-696.
10. Fraga M.F., Ballestar E., Paz M.F., Ropero S., Setien F., Ballestar M.L., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:10604-10609.
11. Gregor Z., Joffe L. Senile macular changes in the black African. The British Journal of Ophthalmology 1978, 62:547-550.
12. Haiman C.A., Stram D.O., Wilkens L.R., Pike M.C., Kolonel L.N., Henderson B.E., et al. Ethnic and racial differences in the smoking-related risk of lung cancer. The New England Journal of Medicine 2006, 354:333-342.
13. Herscu P., Hoover T.A., Randolph A.G. Clinical prediction rules: New opportunities for pharma. Drug Discovery Today 2009, 14:1143-1149.
14. Igarashi T. The duration of toxicity studies required to support repeated dosing in clinical investigation-A toxicologists opinion. CMR workshop: The timing of toxicological studies to support clinical trials 1994, 67-74. Kluwer, Boston. N.M.C. Parkinson, C. Lumley, S.R. Walker (Eds.).
15. Igarashi T., Nakane S., Kitagawa T. Predictability of clinical adverse reactions of drugs by general pharmacology studies. The Journal of Toxicological Sciences 1995, 20:77-92.
16. Igarashi T., Yabe T., Noda K. Study design and statistical analysis of toxicokinetics: A report of JPMA investigation of case studies. The Journal of Toxicological Sciences 1996, 21:497-504.
17. Jansen R.C. Studying complex biological systems using multifactorial perturbation. Nature Reviews. Genetics 2003, 4:145-151.
18. Javierre B.M., Fernandez A.F., Richter J., Al-Shahrour F., Martin-Subero J.I., Rodriguez-Ubreva J., et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Research 2010, 20:170-179.
19. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British Journal of Cancer 2001, 84:1424-1431.
20. Kasowski M., Grubert F., Heffelfinger C., Hariharan M., Asabere A., Waszak S.M., et al. Variation in transcription factor binding among humans. Science 2010, 328:232-235.
21. LaFollette H., Shanks N. Brute science: Dilemmas of animal experimentation 1996, Routledge, London/New York.
22. Litchfield J.T. Symposium on clinical drug evaluation and human pharmacology. XVI. Evaluation of the safety of new drugs by means of tests in animals. Clinical Pharmacology and Therapeutics 1962, 3:665-672.
23. Lumley C. Clinical toxicity: Could it have been predicted? Premarketing experience. Animal toxicity studies: Their relevance for man 1990, 49-56. Quay, Lancaster. C. Lumley, S. Walker (Eds.).
24. Mayr E. This is biology: The science of the living world 1998, Belknap Press, Cambridge, MA.
25. Miklos G.L.G. The human cancer genome project-One more misstep in the war on cancer. Nature Biotechnology 2005, 23:535-537.
26. Miska D. Biotech's twentieth birthday blues. Nature Reviews. Drug Discovery 2003, 2:231-233.
27. Nijhout H.F. The importance of context in genetics. American Scientist 2003, 91:416-423.
28. Ottino J.M. Engineering complex systems. Nature 2004, 427:399.
29. Pearson H. Surviving a knockout blow. Nature 2002, 415:8-9.
30. Regenberg A., Mathews D.J., Blass D.M., Bok H., Coyle J.T., Duggan P., et al. The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. Journal of Cerebral Blood Flow and Metabolism 2009, 29:1-9.
31. Shanks N., Greek R. Animal models in light of evolution 2009, Brown Walker, Boca Raton.
32. Shanks N., Greek R., Greek J. Are animal models predictive for humans?. Philosophy, Ethics and Humanities in Medicine 2009, 4:2.
33. Shelley C. Why test animals to treat humans? On the validity of animal models. Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 2010, 41:292-299.
34. Sietsema W.K. The absolute oral bioavailability of selected drugs. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1989, 27:179-211.
35. Simon V. Wanted: Women in clinical trials. Science 2005, 308:1517.
36. Smith R.L., Caldwell J. Drug metabolism in non-human primates. Drug metabolism-From microbe to man 1977, 331-356. Taylor & Francis, London. D.V. Parke, R.L. Smith (Eds.).
37. Thein S.L. Genetic modifiers of beta-thalassemia. Haematologica 2005, 90:649-660.
38. Van Regenmortel M.H. Reductionism and complexity in molecular biology. Scientists now have the tools to unravel biological and overcome the limitations of reductionism. EMBO Reports 2004, 5:1016-1020.
39. von Herrath M., Nepom G.T. Remodeling rodent models to mimic human type 1 diabetes. European Journal of Immunology 2009, 39:2049-2054.
40. Weaver J.L., Staten D., Swann J., Armstrong G., Bates M., Hastings K.L. Detection of systemic hypersensitivity to drugs using standard guinea pig assays. Toxicology 2003, 193:203-217.
41. Weiss S.T., McLeod H.L., Flockhart D.A., Dolan M.E., Benowitz N.L., Johnson J.A., et al. Creating and evaluating genetic tests predictive of drug response. Nature Reviews Drug Discovery 2008, 7:568-574.
42. Wong A.H., Gottesman I.I., Petronis A. Phenotypic differences in genetically identical organisms: The epigenetic perspective. Human Molecular Genetics 2005, 14(R1):R11-R18.